SEITO Biologics

SEITO Biologics AG is a preclinical-stage biotechnology company developing novel immunotherapies for autoimmune and chronic inflammatory diseases. SEITO Biologics combines nearly two decades of groundbreaking immunology research and the development of novel immunotherapies with entrepreneurial expertise. Its vision is to become a biotechnology leader in developing treatments for immune-mediated diseases. Its therapies can enhance the regulatory T cells in our bodies to restore immune balance. The company is built on discoveries from the Department of Immunology at the University of Zurich and is a spin-off of the University of Zurich.